Xylazine Test Strips

The District of Columbia is soliciting a procurement opportunity for Xylazine Test Strips, a critical public health and safety contract targeting substance abuse detection and monitoring. This contract appears focused on acquiring specialized diagnostic tools designed to identify the presence of xylazine, a potent veterinary tranquilizer increasingly detected in illicit drug supplies. The procurement is structured as a competitive solicitation with a posting date of February 4, 2025, and a proposal submission deadline of February 18, 2025. Prospective vendors must demonstrate technical capabilities in producing accurate, reliable test strip technology capable of detecting xylazine in various substance samples. The contract likely requires comprehensive documentation of test strip accuracy, sensitivity, and reproducibility, with potential requirements for detailed laboratory validation data. Evaluation criteria will presumably include product performance metrics, manufacturing quality standards, cost-effectiveness, and potential integration with existing public health testing protocols.

The procurement may include set-aside provisions or preferences for small businesses, minority-owned enterprises, or local District of Columbia vendors, though specific designations are not explicitly detailed in the provided information. While no incumbent vendors are identified, the contract suggests a targeted procurement addressing emerging public health challenges related to drug monitoring and harm reduction strategies. The potential award value is not specified, but given the specialized nature of xylazine test strips and their critical public health applications, the budget could range from moderate to significant depending on anticipated quantity and technical specifications. Potential respondents should anticipate rigorous qualification requirements, including demonstrable expertise in medical diagnostic technology, substance detection methodologies, and compliance with relevant public health regulations. Vendors will likely need to provide comprehensive product specifications, testing protocols, and evidence of regulatory compliance to be considered for this contract opportunity.